Daiwa Securities Group Inc. Summit Therapeutics Inc. Transaction History
Daiwa Securities Group Inc.
- $27.1 Billion
- Q2 2025
A detailed history of Daiwa Securities Group Inc. transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Daiwa Securities Group Inc. holds 2,564 shares of SMMT stock, worth $54,741. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,564
Previous 14,259
82.02%
Holding current value
$54,741
Previous $275,000
80.0%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding SMMT
# of Institutions
263Shares Held
90.3MCall Options Held
4.71MPut Options Held
3.17M-
Baker Bros. Advisors LP New York, NY33.7MShares$720 Million7.27% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.67MShares$185 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$169 Million0.0% of portfolio
-
State Street Corp Boston, MA4.02MShares$85.8 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.91MShares$83.4 Million0.01% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $4.3B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...